









Markets
/
Stocks
/
nasdaq-sepn
/

Septerna Inc

SEPN

25.410USD

+0.970+3.97%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.13BMarket Cap

1.85P/E TTM



Septerna Inc

25.410

+0.970+3.97%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Septerna Inc

Currency: USD Updated: 2026-02-06

Key Insights

Septerna Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 14 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.86.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Septerna Inc's Score

Industry at a Glance

Industry Ranking

14 / 392

Overall Ranking

100 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Septerna Inc Highlights

StrengthsRisks

Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.07M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.07M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 1.85, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 45.24M shares, decreasing 8.09% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 989.00 shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

33.857

Target Price

+38.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Septerna Inc is 9.55, ranking 1 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 21.50M, representing a year-over-year increase of 12113.07%, while its net profit experienced a year-over-year increase of 139.82%.

Score

Industry at a Glance

Previous score

9.55

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Septerna Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Septerna Inc is 6.52, ranking 259 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 1.85, which is 16.42% below the recent high of 2.15 and 276.57% above the recent low of -3.26.

Score

Industry at a Glance

Previous score

6.52

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 14/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Septerna Inc is 8.25, ranking 147 out of 392 in the Biotechnology & Medical Research industry. The average price target is 29.00, with a high of 34.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

33.857

Target Price

+38.53%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Septerna Inc

SEPN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Septerna Inc is 7.22, ranking 88 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 28.03 and the support level at 22.90, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.91

Change

0.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.087

Sell

RSI(14)

49.168

Neutral

STOCH(KDJ)(9,3,3)

55.450

Buy

ATR(14)

1.460

Low Volatility

CCI(14)

-19.588

Neutral

Williams %R

51.472

Neutral

TRIX(12,20)

-0.367

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

25.070

Buy

MA10

24.757

Buy

MA20

25.506

Sell

MA50

26.559

Sell

MA100

23.517

Buy

MA200

17.184

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Septerna Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.03%, representing a quarter-over-quarter increase of 0.29%. The largest institutional shareholder is The Vanguard, holding a total of 1.51M shares, representing 3.37% of shares outstanding, with 50.45% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Third Rock Ventures, LLC

10.43M

RA Capital Management, LP

7.00M

Driehaus Capital Management, LLC

4.92M

+5.12%

BVF Partners L.P.

4.02M

-8.65%

Samsara BioCapital, LLC

3.15M

Invus Public Equities Advisors, LLC

2.20M

The Vanguard Group, Inc.

Star Investors

1.52M

+7.38%

Goldman Sachs & Company, Inc.

1.42M

+0.06%

Avoro Capital Advisors LLC

1.34M

+8.08%

BlackRock Institutional Trust Company, N.A.

1.32M

+4.97%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Septerna Inc is 4.58, ranking 81 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.